Amgen Inc.

Tularik Limited

Hailing Hsu

Frederick W Jacobsen

Ian Nevin Foltz

Gunasekaran Kannan

Taruna Arora

Hosung Min

Fei Xiong

Wayne H Tsuji

Ming Zhang

David V Goeddel

William James Boyle

Scott Kenneth Wooden

Vijay R Baichwal

Jianing Huang

Kenneth William Walker

Edward John Belouski

William Rees

Dominique Christian Borie

Michelle Hortter

Wei-Jian Pan

Barbara Anne Sullivan

Barbara Sullivan

Dominique Borie

Described herein are bispecific proteins specific for BAFF and B7RP1, nucleic acids encoding such proteins, methods of making such proteins, and uses for such proteins.

Proteins specific for BAFF and B7RP1 and uses thereof

The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-&#x3b1;. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-&#x3b1;. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-&#x3b1; antigen binding proteins, and pharmaceutical formulations thereof.

Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof

Proteins specific for BAFF and B7RP1

There is provided a method of treating a subject afflicted with a condition that is associated with inappropriate trafficking of cells expressing alpha4beta7 to the gastrointestinal tract, comprising administering to the subject an alpha4beta7 heterodimer specific antibody in an amount and at an interval sufficient to ameliorate the condition.

Administration of alpha4beta7 hetero-dimer-specific antibody

There are disclosed alpha4beta7 heterodimer-specific antigen binding proteins, nucleic acids encoding them, and methods of making and using them.

Methods of using an alpha-4-beta-7 heterodimer specific antagonist antibody

The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence DzLzwherein zis an amino acid residue and zis threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formula(X)&#x2014;V&#x2014;(X)wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.

Peptides and related molecules that bind to TALL-1

Alpha-4-beta-7 heterodimer specific antagonist antibody

The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence DzLzwherein zis an amino acid residue and zis threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formula(X)-V-(X)wherein V1 is a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.

Alpha-4 beta-7 heterodimer specific antagonist antibody

The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence DzLzwherein zis an amino acid residue and zis threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae wherein the substituents are as defined in the specification. The invention further comprises compositions of matter of the formula(X)&#x2014;V&#x2014;(X)wherein Vis a vehicle that is covalently attached to one or more of the above TALL-1 modulating compositions of matter. The vehicle and the TALL-1 modulating composition of matter may be linked through the N- or C-terminus of the TALL-1 modulating portion. The preferred vehicle is an Fc domain, and the preferred Fc domain is an IgG Fc domain.

The present invention provides a purified polynucleotide encoding a novel polypeptide, designated Fhm, which belongs to the TNF gene superfamily; to purified Fhm polypeptide molecules; to antibodies that bind Fhm; to materials comprising such molecules; and to methods of using such molecules.

Fhm a novel member of the TNF ligand supergene family: materials and methods for interaction modulators

Growing community of inventors

Moorpark, CA, United States of America

Hailing Hsu